Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q2 2015 · 10-Q
Revenue$367.00K$367.00K— vs Q2 2014 Net Income-$1.65M-$1.65MN/M vs Q2 2014 EPS Diluted-$0.02-$0.02N/M vs Q2 2014 Operating Income-$1,666,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,624,000N/M Margins · derivedOperating margin-454.0%
Net margin-450.4%
ended Dec 31, 2014 · filed Feb 23, 2015 · 54 d after period end